Evidence map›Paper›PMID 38036391›Full record

ReviewTrends in molecular medicine2024

Redefining metalloproteases specificity through network proteolysis.

Orit Kollet, Alakesh Das, Nikos Karamanos, Ulrich Auf dem Keller, Irit Sagi

Open access · bronzeAbstract readReview
In one paragraph

Review in Trends in molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Small Molecule Protease Inhibitors as Model Peptidomimetics.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Orit KolletThe Weizmann Institute of Science, Department of Immunology and Regenerative Biology, Rehovot, Israel.
Alakesh DasThe Weizmann Institute of Science, Department of Immunology and Regenerative Biology, Rehovot, Israel.
Nikos KaramanosUniversity of Patras, Biochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, Patras, Greece.
Ulrich Auf dem KellerTechnical University of Denmark, Department of Biotechnology and Biomedicine, Lyngby, Denmark.
Irit SagiThe Weizmann Institute of Science, Department of Immunology and Regenerative Biology, Rehovot, Israel. Electronic address: irit.sagi@weizmann.ac.il.
Weizmann Institute of Science · ILTechnical University of Denmark · DKUniversity of Patras · GR

Funding

Targeting MT1-MMP to inhibit pathologic inflammation in TBR21AI146813 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BARCZAK, AMY K · 2019 to 2020
$418k
NIAID NIH HHS R21 AI146813
6 · The paper itself

Abstract

Proteolytic processes on cell surfaces and extracellular matrix (ECM) sustain cell behavior and tissue integrity in health and disease. Matrix metalloproteases (MMPs) and a disintegrin and metalloproteases (ADAMs) remodel cell microenvironments through irreversible proteolysis of ECM proteins and cell surface bioactive molecules. Pan-MMP inhibitors in inflammation and cancer clinical trials have encountered challenges due to promiscuous activities of MMPs. Systems biology advances revealed that MMPs initiate multifactorial proteolytic cascades, creating new substrates, activating or suppressing other MMPs, and generating signaling molecules. This review highlights the intricate network that underscores the role of MMPs beyond individual substrate-enzyme activities. Gaining insight into MMP function and tissue specificity is crucial for developing effective drug discovery strategies and novel therapeutics. This requires considering the dynamic cellular processes and consequences of network proteolysis.

Indexed as

MetalloproteasesNeoplasmsExtracellular MatrixHumansInflammationProteolysisTumor MicroenvironmentMetalloproteasesbiomarkersdegradomicsextracellular matrix (ECM) remodelingmatrix metalloproteases (MMPs)protease specificityproteolytic network

Identifiers

PMID38036391
PMCPMC11004056
OpenAlexW4389120789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.